Abstract:Depression is associated with a lowered degree of esterification of serum cholesterol, an increased C20:4ω6/C20:5ω3 ratio and decreases in ω3 fractions in fatty acids (FAs) or in the red blood cell membrane. The aims of the present study were to examine: (i) serum phospholipid and cholesteryl ester compositions of individual saturated fatty acids (SFAs), monounsaturated FAs (MUFAs) and polyunsaturated FAs (PUFAs) in major depressed patients vs. healthy volunteers; (ii) the relationships between the above FAs and lowered serum zinc (Zn), a marker of the inflammatory response in depression; and (iii) the effects of subchronic treatment with antidepressants on FAs in depression. The composition of the FAs was determined by means of thin layer chromatography in conjunction with gas chromatography. Lipid concentrations were assayed by enzymatic colorimetric methods. The oxidative potential index (OPI) of FAs was computed in 34 major depressed inpatients and 14 normal volunteers. Major depression was associated with: increased MUFA and C22:5ω3 proportions and increased C20:4ω6/C20:5ω3 and C22:5ω6/C22:6ω3 ratios; lower C22:4ω6, C20:5ω3 and C22:5ω3 fractions in phospholipids; lower C18:3ω3, C20:5ω3 and total (Σ)ω3 FAs, and higher C20:4ω6/C20:5ω3 and Σω6/Σω3 ratios in cholesteryl esters; lower serum concentrations of phospholipids and cholesteryl esters; and a decreased OPI. In depression, there were significant and positive correlations between serum Zn and C20:5ω3 and C22:6ω3 fractions in phospholipids; and significant inverse correlations between serum Zn and the Σω6/Σω3, C20:4ω6/C20:5ω3, and C22:5ω6/C22:6ω3 ratios in phospholipids. There was no significant effect of antidepressive treatment on any of the FAs. The results show that, in major depression, there is a deficiency of ω3 PUFAs and a compensatory increase in MUFAs and C22:5ω6 in phospholipids. The results suggest that: (i) there is an abnormal metabolism of ω3 PUFAs in depression; (ii) the FA alterations in depression are related to the inflammatory response in that illness; and (iii) the disorders may persist despite successful antidepressant treatment.

Lowered Zinc and Copper Levels in Drug-Naïve Patients with Major Depression: Effects of Antidepressants, Ketoprofen and Immune Activation.

Lower Serum Zinc in Major Depression is a Sensitive Marker of Treatment Resistance and of the Immune/inflammatory Response in That Illness.

Total and Ionized Calcium and Magnesium Are Significantly Lowered in Drug-Naïve Depressed Patients: Effects of Antidepressants and Associations with Immune Activation

Lower Serum Zinc in Major Depression in Relation to Changes in Serum Acute Phase Proteins.

Plasma Indoleamine-2,3-Dioxygenase (IDO) is Increased in Drug-Naï Ve Major Depressed Patients and Treatment with Sertraline and Ketoprofen Normalizes IDO in Association with Pro-Inflammatory and Immune- Regulatory Cytokines

Ketoprofen As an Add-on Treatment to Sertraline for Drug-Na&iuml;ve Major Depressed Patients: Normalization of Plasma Levels of Indoleamine-2,3-Dioxygenase in Association with Pro-Inflammatory and Immune Regulatory Cytokines

Fluoxetine Treatment for Major Depression Decreases the Plasma Levels of Cytokines

The Study of Level Changes of Serum Cytokine, C-reactive Protein and Zinc in Patients with Depression at Pre- and Post-Treatment of Paroxetine

Changes in the Serum Levels of Inflammatory Cytokines in Antidepressant Drug-Naïve Patients with Major Depression

Increased Serum IL-6 and IL-1 Receptor Antagonist Concentrations in Major Depression and Treatment Resistant Depression.

Serotonin-immune Interactions in Major Depression: Lower Serum Tryptophan As a Marker of an Immune-Inflammatory Response

Serum Copper and Zinc Levels Correlate with Biochemical Metabolite Ratios in the Prefrontal Cortex and Lentiform Nucleus of Patients with Major Depressive Disorder

Peripheral Alterations in Cytokine and Chemokine Levels after Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis

Lowered Ω3 Polyunsaturated Fatty Acids in Serum Phospholipids and Cholesteryl Esters of Depressed Patients

Negative Immunoregulatory Effects of Antidepressants: Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion

Neuroimmunological aspects of the alterations in zinc homeostasis in the pathophysiology and treatment of depression

Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers.

Hypozincemia in depression

Serum Interleukin Levels and Insulin Resistance in Major Depressive Disorder

Increased Neopterin and Interferon-Gamma Secretion and Lower Availability of L-tryptophan in Major Depression: Further Evidence for an Immune Response

Increased Plasma Concentrations of Interleukin-6, Soluble Interleukin-6, Soluble Interleukin-2 and Transferrin Receptor in Major Depression.